The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial

JACC: Heart Failure

Volumn 2, Issue 6, 2014, Pages 641-649

  Mortensen, Svend A ^a   Rosenfeldt, Franklin ^b   Kumar, Adarsh ^c   Dolliner, Peter ^d   Filipiak, Krzysztof J ^e   Pella, Daniel ^f   Alehagen, Urban ^g   Steurer, Günter ^d   Littarru, Gian P ^h  

^a Mental Health Services CPH   (Denmark)

^b MONASH UNIVERSITY   (Australia)

^c GOVERNMENT MEDICAL COLLEGE   (India)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f Med Faculty of Safarik University   (Slovakia)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Chronic heart failure; Coenzyme Q10; Metabolic therapy; Randomized controlled trial; Ubiquinone

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PLACEBO; UBIDECARENONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UBIQUINONE; VITAMIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WALKING SPEED; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; CLINICAL TRIAL; DEATH, SUDDEN, CARDIAC; HOSPITALIZATION; METABOLISM; MORTALITY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

BIOLOGICAL MARKERS; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; UBIQUINONE; VITAMINS;

EID: 84923212398     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.06.008     Document Type: Article

References (38)

1. Hadj A., Pepe S., Rosenfeldt F. The clinical application of metabolic therapy for cardiovascular disease. Heart Lung Circ 2007, 16(Suppl 3):S56-S64.
2. Scolletta S., Biagioli B. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed Pharmacother 2010, 64:203-207.
3. Sheeran F.L., Pepe S. Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate. Biochim Biophys Acta 2006, 1757:543-552.
4. Beyer R., Ernster L. The antioxidant role of coenzyme Q. Highlights in Ubiquinone Research 1990, 191-213. Taylor and Francis, London. G. Lenaz, O. Barnabei, A.B.M. Rabbi (Eds.).
5. Littarru G.P. Location and function of coenzyme Q in the respiratory chain. Energy and Defense. Facts and Perspectives on Coenzyme Q10 in Biology and Medicine 1994, 14-22. Casa Editrice Scientifica Internazionale, Rome.
6. Folkers K., Vadhanavikit S., Mortensen S. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 1985, 82:901-904.
7. Molyneux S.L., Florkowski C.M., George P.M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. JAm Coll Cardiol 2008, 52:1435-1441.
8. McMurray J.J.V., Dunselman P., Wedel H., et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heartfailure). JAm Coll Cardiol 2010, 56:1196-1204.
9. Soja A., Mortensen S. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997, 18(Suppl):s159-s168.
10. Sander S., Coleman C.I., Patel A.A., Kluger J., White C.M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. JCard Fail 2006, 12:464-472.
11. Fotino A., Thompson-Paul A., Bazzano L. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr 2013, 97:268-275.
12. Rosenfeldt F., Hilton D., Pepe S., Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003, 18:91-100.
13. Madmani M.E., Solaiman A.Y., Tamr Agha K., et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev 2013, (9):CD008684.
14. Mortensen S. Overview on coenzyme Q10 asadjunctive therapy in chronic heart failure: rationale, design and end-points of "Q-symbio"-a multinational trial. Biofactors 2003, 18:79-89.
15. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
16. Cleland J.G.F., Daubert J.-C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. NEngl J Med 2005, 352:1539-1549.
17. Rosenfeldt F., Marasco S., Lyon W., et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and invitro contractility of myocardial tissue. JThorac Cardiovasc Surg 2005, 129:25-32.
18. Littarru G., Mosca F., Fattorini D., Bompadre S., Battino M. Assay of coenzyme Q10 in plasma by a single dilution step. Methods Enzymol 2004, 378:170-176.
19. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999, 230:177-181.
20. Folkers K., Moesgaard S., Morita M. Aone year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol Aspects Med 1994, 15(Suppl):s281-s285.
21. Weis M., Mortensen S., Rassing M., Møller-Sonnergaard J., Poulsen G., Rasmussen S. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994, 15(Suppl):s273-s280.
22. No authors listed Aplacebo-controlled trial of captopril in refractory chronic congestive heart failure: Captopril Multicenter Research Group. JAm Coll Cardiol 1983, 2:755-763.
23. Packer M., Colucci W.S., Sackner-Bernstein J.D., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996, 94:2793-2799.
24. Caldentey G., Khairy P., Roy D., et al. Prognostic value of the physical examination in patients with heart failure and atrial fibrillation: insights from the AF-CHF trial (Atrial Fibrillation and Chronic Heart Failure). JAm Coll Cardiol HF 2014, 2:15-23.
25. Hofman-Bang C., Rehnqvist N., Swedberg K., Wiklund I., Åström H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure: the Q10 Study Group. JCard Fail 1995, 1:101-107.
26. Townend J.N., Littler W.A. Angiotensin converting enzyme inhibitors in heart failure: how good are they?. Br Heart J 1993, 69:373-375.
27. Morisco C., Trimarco B., Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993, 71(Suppl):134-136.
28. Haas R.H. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 2007, 7(Suppl):S136-S145.
29. Folkers K. Heart failure is a dominant deficiency of coenzyme Q10 and challenges for future clinical research on CoQ10. Clin Investig 1993, 71(Suppl):s51-s54.
30. Opie L.H. The metabolic vicious cycle in heart failure. Lancet 2004, 364:1733-1734.
31. Belardinelli R., Macaj A., Lacalaprice F., et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006, 27:2675-2681.
32. Ferrari R., Guardigli G., Mele D., Percoco G., Ceconi C., Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004, 10:1699-1711.
33. Ghirlanda G., Oradei A., Manto A., et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. JClin Pharmacol 1993, 33:226-229.
34. Mortensen S., Leth A., Agner E., Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997, 18(Suppl):s137-s144.
35. Kalén A., Appelkvist E., Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids 1989, 24:579-584.
36. Alehagen U., Johansson P., Björnstedt M., Rosén A., Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 2013, 167:1860-1866.
37. Soukoulis V., Dihu J.B., Sole M., et al. Micronutrient deficiencies an unmet need in heart failure. JAm Coll Cardiol 2009, 54:1660-1673.
38. Krim S.R., Campbell P., Lavie C.J., Ventura H. Micronutrients in chronic heart failure. Curr Heart Fail Rep 2013, 10:46-53.